Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo

Journal of Urology

Volumn 175, Issue 4, 2006, Pages 1422-1427

  Crawford, E David ^a   Wilson, Shandra S ^a   McConnell, John D ^b   Slawin, Kevin M ^c   Lieber, Michael C ^d   Smith, Joseph A ^e   Meehan, Alan G ^f   Bautista, Oliver M ^g   Noble, William R ^g   Kusek, John W ^h   Nyberg, Leroy M ^h   Roehrborn, Claus G ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Causality; Disease progression; Prostatic hyperplasia

Indexed keywords

DOXAZOSIN; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; FOLLOW UP; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RECURRENT INFECTION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; URINARY TRACT INFECTION; URINE FLOW RATE; URINE INCONTINENCE; URINE RETENTION; URINE VOLUME;

EID: 33644588425     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00708-1     Document Type: Article

References (18)

1. J.D. McConnell The pathophysiology of benign prostatic hyperplasia J Androl 12 1991 356
2. G. Welch, K. Weinger, M.J. Barry Quality-of-life impact of lower urinary tract symptom severity results from the Health Professionals Follow-up Study Urology 59 2002 245
3. J.D. McConnell, C.G. Roehrborn, O.M. Bautista, G.L. Andriole Jr., C.M. Dixon, J.W. Kusek The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387
4. P. Boyle, A.L. Gould, C.G. Roehrborn Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride meta-analysis of randomized clinical trials Urology 48 1996 398
5. C.G. Roehrborn, J.D. McConnell, M. Lieber, S. Kaplan, J. Geller, G.H. Malek PLESS Study Group Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia Urology 53 1999 473
6. C.G. Roehrborn, P. Boyle, D. Bergner, T. Gray, M. Gittelman, T. Shown PLESS Study Group Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate results of a four-year, randomized trial comparing finasteride versus placebo Urology 54 1999 662
7. M.J. Marberger, J.T. Andersen, J.C. Nickel, M.P. Malice, M. Gabriel, F. Pappas Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials Eur Urol 38 2000 563
8. S.A. Kaplan, H.L. Holtgrewe, R. Bruskewitz, B. Saltzman, D. Mobley, P. Narayan Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia Urology 57 2001 1073
9. C.G. Roehrborn, M. Malice, T.J. Cook, C.J. Girman Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH a comprehensive analysis of the pooled placebo groups of several large clinical trials Urology 58 2001 210
10. C.G. Roehrborn, J.D. McConnell, B. Saltzmann, D. Bergner, T. Gray, P. Narayan Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes Eur Urol 42 2002 1
11. S.J. Berry, D.S. Coffey, P.C. Walsh, L.L. Ewing The development of human benign prostatic hyperplasia with age J Urol 132 1984 474
12. C.J. Girman, S.J. Jacobsen, H.A. Guess, J.E. Oesterling, C.G. Chute, L.A. Panser Natural history of prostatism relationship among symptoms, prostate volume and peak urinary flow rate J Urol 153 1995 1510
13. J.B. Meigs, M.J. Barry, E. Giovannucci, E.B. Rimm, M.J. Stampfer, I. Kawachi Incidence rates and risk factors for acute urinary retention the health professionals followup study J Urol 162 1999 376
14. S.J. Jacobsen, D.J. Jacobson, C.J. Girman, R.O. Roberts, T. Rhodes, H.A. Guess Natural history of prostatism risk factors for acute urinary retention J Urol 158 1997 481
15. S.J. Jacobsen, D.J. Jacobson, C.J. Girman, R.O. Roberts, T. Rhodes, H.H. Guess Treatment for benign prostatic hyperplasia among community dwelling men the Olmsted County study of urinary symptoms and health status J Urol 162 1999 1301
16. Y.K. Fong, S. Milani, B. Djavan Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia Curr Opin Urol 15 2005 35
17. B. Djavan, Y.K. Fong, M. Harik, S. Milani, A. Reissigl, A. Chaudry Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years Urology 64 2004 1144
18. Vital Statistics of the United States, 1994 1998 Centers for Disease Control and Prevention/National Center for Health Statistics Hyattsville, Maryland Preprint of Volume II, Mortality, Part A, Section 6, Life Tables.